Jennison Associates
STRO icon

Jennison Associates’s Sutro Biopharma STRO Stock Holding History

Jennison Associates’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,431
Closed -$1.31M – 666
2019
Q3 		$1.31M Sell
14,431
-1,456
-9% -$147K ﹤0.01% 521
2019
Q2 		$1.81M Buy
15,887
+2,108
+15% +$232K ﹤0.01% 505
2019
Q1 		$1.57M Buy
13,779
+474
+4% +$49.3K ﹤0.01% 505
2018
Q4 		$1.2M Sell
13,305
-1,695
-11% -$205K ﹤0.01% 532
2018
Q3 		$2.25M Buy
+15,000
New +$2.27M ﹤0.01% 517

Other funds holding STRO

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
VM
VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates's STRO Position: Q4 2019 in Review

Jennison Associates sold out of Sutro Biopharma (STRO) in Q4 2019, closing a stake of 14,431 shares — an estimated $1.31M sold.

Jennison Associates first reported a position in STRO in Q3 2018 and held it in 5 quarters. The position peaked at $2.25M in Q3 2018. 64 funds tracked by Wall St. Rank hold STRO as of Q4 2019.

  • Jennison Associates reported no remaining Sutro Biopharma position as of Q4 2019 after selling out during the quarter.
  • Jennison Associates sold 14,431 Sutro Biopharma shares in Q4 2019, an estimated $1.31M.
  • Jennison Associates first reported a position in Sutro Biopharma in Q3 2018 and held it in 5 quarters.
  • Jennison Associates's Sutro Biopharma position peaked at $2.25M in Q3 2018.
  • 64 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2019.

Based on Jennison Associates's 13F filing for Q4 2019, filed 7 Feb 2020.